Skye Bioscience, Inc.SKYENASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
27.27%
↑ 252% above average
Average (39q)
-17.95%
Historical baseline
Range
High:468.50%
Low:-345.58%
CAGR
-1.3%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 27.27% |
| Q2 2025 | -57.14% |
| Q1 2025 | -16.67% |
| Q4 2024 | -140.00% |
| Q3 2024 | 50.00% |
| Q2 2024 | -11.11% |
| Q1 2024 | 50.00% |
| Q4 2023 | 88.64% |
| Q3 2023 | -296.25% |
| Q2 2023 | 41.61% |
| Q1 2023 | 72.55% |
| Q4 2022 | -215.82% |
| Q3 2022 | 36.80% |
| Q2 2022 | 0.00% |
| Q1 2022 | -63.40% |
| Q4 2021 | -39.09% |
| Q3 2021 | 56.00% |
| Q2 2021 | 0.00% |
| Q1 2021 | -89.39% |
| Q4 2020 | -4.76% |
| Q3 2020 | 35.05% |
| Q2 2020 | 39.56% |
| Q1 2020 | -109.40% |
| Q4 2019 | 468.50% |
| Q3 2019 | -130.90% |
| Q2 2019 | 209.09% |
| Q1 2019 | -133.45% |
| Q4 2018 | -195.24% |
| Q3 2018 | 21.61% |
| Q2 2018 | 78.03% |
| Q1 2018 | -345.58% |
| Q4 2017 | -30.65% |
| Q3 2017 | 35.70% |
| Q2 2017 | 55.14% |
| Q1 2017 | 1.92% |
| Q4 2016 | -18.53% |
| Q3 2016 | -258.27% |
| Q2 2016 | 137.50% |
| Q1 2016 | -113.22% |
| Q4 2015 | 45.87% |